Vivek Subbiah: Fragmentation in medicine harms patients and hinders research

Vivek Subbiah shared a post on LinkedIn about a recent paper “Fragmentation in medicine harms patients and hinders research” published in Nature Medicine.

Author: Vivek Subbiah

“For your weekend reading. Delighted to share my world view published in Nature Medicine.

Fragmentation in medicine harms patients and hinders research.

Transforming the fragmented silos of medicine into a wheel of collaboration holds the key to tackling complex health challenges for generations to come.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.